CD19 and acute lymphoblastic leukemia: In recent years, CD19-targeted CAR T-cell therapy has yielded spectacular clinical responses against hematologic liquid tumors (44), including up to 90% complete response in relapsed or treatment-refractory acute lymphoblastic leukemia (ALL) patients (45).